drugset / Trial / NCT01892241
Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Patients with spontaneous decline of HBV DNA were non-randomly assigned to accept peginterferon alfa-2a or entecavir therapy, or didn't accept any antiviral regiment.
Timeline
- Start
- 2010-01
- Primary completion
- 2012-11
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Entecavir | Small molecule | 0.5 mg | Oral |
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |